利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

48 条记录 (耗时 0.041 秒)

    Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase
    41.
    发明授权
    Nucleic acids and polypeptides related to a guanine exchange factor of Rho GTPase 失效

    公开(公告)号：US07148002B2

    公开(公告)日：2006-12-12

    申请号：US10448162

    申请日：2003-05-27

    申请人： Matthew J. Hart

    发明人： Matthew J. Hart

    IPC分类号： C12Q1/00 ,  C12Q1/48

    CPC分类号： C07K16/18 ,  A61K38/00 ,  A61K48/00 ,  C07K14/82 ,  C12Q1/6876

    摘要： The present invention relates to all aspects of a guanine exchange factor (GEF), for example, a Rho-GEF, such as p115 Rho-GEF. A GEF modulates cell signaling pathways, both in in vitro and in vivo, by modulating the activity of a GTPase. By way of illustration, a p115 Rho-GEF, which modulates the activity of a Rho GTPase, is described. However, the present invention relates to other GEFs, especially other Rho-GEFs. The present invention particularly relates to an isolated p115 Rho-GEF polypeptide or fragments of it, a nucleic acid coding for p115 Rho-GEF or fragments of it, and derivatives of the polypeptide and nucleic acid. The invention also relates to methods of using such polypeptides, nucleic acids, or derivatives thereof, e.g., in therapeutics, diagnostics, and as research tools. Another aspect of the present invention involves antibodies and other ligands which recognize p115 Rho-GEF, regulators of p115 Rho-GEF activity, and methods of treating pathological conditions associated or related to a Rho GTPase.

    Modulators of BRCA1 activity
    43.
    发明授权
    Modulators of BRCA1 activity 失效
    BRCA1活性调节剂

    公开(公告)号：US5948643A

    公开(公告)日：1999-09-07

    申请号：US968751

    申请日：1997-08-13

    申请人： Bonnee Rubinfeld ,  Paul G. Polakis ,  Carol Lingenfelter ,  Terilyn T. Vuong

    发明人： Bonnee Rubinfeld ,  Paul G. Polakis ,  Carol Lingenfelter ,  Terilyn T. Vuong

    IPC分类号： C07K14/47 ,  C12P21/06 ,  C07H21/02 ,  C12N5/00 ,  C12N15/00

    CPC分类号： C07K14/4702

    摘要： Compositions of matter consisting of a family of related nucleotide sequences that encode proteins, termed BRCA1 Modulator Proteins, that bind to the tumor suppressor gene product BRCA1, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the BRCA1 Modulator Proteins have an apparent molecular weight of 45-97 kdaltons and are characterized by having at least one leucine zipper domain, and optionally a zinc finger domain.

    摘要翻译： 由编码蛋白质的相关核苷酸序列家族组成的物质组成，称为BRCA1调节蛋白，其结合肿瘤抑制基因产物BRCA1，以及使用其编码的核苷酸序列和蛋白质的方法诊断和/或治疗疾病 其中BRCA1调节蛋白的表观分子量为45-97千道尔顿，其特征在于具有至少一个亮氨酸拉链结构域和任选的锌指结构域。

    Cytopathic viruses for therapy and prophylaxis of neoplasia
    44.
    发明授权
    Cytopathic viruses for therapy and prophylaxis of neoplasia 失效
    用于治疗和预防肿瘤的细胞病变病毒

    公开(公告)号：US5856181A

    公开(公告)日：1999-01-05

    申请号：US950275

    申请日：1997-10-14

    申请人： Francis McCormick

    发明人： Francis McCormick

    IPC分类号： A61K35/76 ,  A61K35/761 ,  A61K48/00 ,  C12N7/00 ,  C12N7/04 ,  C12N15/861 ,  C12N5/10 ,  C12N7/01 ,  C07H21/04

    CPC分类号： C12N15/86 ,  A61K35/761 ,  C12N7/00 ,  A61K48/00 ,  C12N2710/10321 ,  C12N2710/10332 ,  C12N2710/10343 ,  C12N2710/10362

    摘要： Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.

    摘要翻译： 提供了通过病毒治疗来治疗肿瘤病症的方法和组合物。 将具有结合和/或失活p53或RB的病毒蛋白的突变病毒给予具有肿瘤的患者，所述肿瘤包含缺乏p53和/或RB功能的细胞。 突变型病毒能够在肿瘤细胞中基本上产生复制表型，但基本上不能在具有基本正常p53和/或RB功能的非复制性非肿瘤细胞中产生复制表型。 在肿瘤细胞中优先产生复制表型导致直接或通过在表达病毒复制表型的细胞中表达细胞毒性基因来赘生性细胞的优先杀伤。

    Human PAK65
    48.
    发明授权
    Human PAK65 失效

    公开(公告)号：US5518911A

    公开(公告)日：1996-05-21

    申请号：US369780

    申请日：1995-01-06

    申请人： Arie Abo ,  George A. Martin

    发明人： Arie Abo ,  George A. Martin

    IPC分类号： G01N33/566 ,  A61K31/70 ,  A61K38/55 ,  A61P25/00 ,  A61P29/00 ,  A61P35/02 ,  A61P37/00 ,  C12N5/10 ,  C12N9/12 ,  C12N15/09 ,  C12P21/04 ,  G01N33/15 ,  C07H21/04 ,  C12N1/20 ,  C12P21/06

    CPC分类号： C12N9/1205

    摘要： A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.